Urquhart Siri A, Quinn Kevin P, Ravi Karthik, Loftus Edward V
Division of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Crohns Colitis 360. 2021 May 12;3(2):otab018. doi: 10.1093/crocol/otab018. eCollection 2021 Apr.
The clinical characteristics and treatment outcomes in patients with eosinophilic esophagitis (EoE) and inflammatory bowel disease (IBD) have not been extensively investigated.
We determined treatment outcomes and frequencies of disease-related complications in patients with EoE and IBD.
Among 69 patients who met inclusion criteria, 39 (56.5%) had a diagnosis of Crohn disease. Clinical and histologic response rates to proton pump inhibitors and topical steroids were 25.9% and 24.4%, respectively.
Lower than expected clinical and histologic response rates for EoE suggest the combination of EoE and IBD is a medically refractory phenotype with more difficult to treat EoE.
嗜酸性食管炎（EoE）和炎症性肠病（IBD）患者的临床特征及治疗结果尚未得到广泛研究。
我们确定了EoE和IBD患者的治疗结果及疾病相关并发症的发生率。
在69例符合纳入标准的患者中，39例（56.5%）诊断为克罗恩病。对质子泵抑制剂和局部类固醇的临床及组织学反应率分别为25.9%和24.4%。
EoE低于预期的临床及组织学反应率表明，EoE与IBD的合并是一种医学上难治的表型，其中EoE更难治疗。
